POAI Reports Earnings
Predictive Oncology (NASDAQ:POAI), a company focused on AI-driven drug discovery and oncologic assay commercialization, released its earnings for the quarter ended June 30, 2025, on August 14, 2025. GAAP revenue fell 96% to $2,682 in Q2 2025 from $67,255 in Q2 2024, as sales of its tumor-specific 3D models and kits nearly disappeared. There were no analyst estimates available for comparison. Operating losses narrowed to $(1,978,895) (GAAP) from $(2,456,669) in the prior-year period, reflecting cost savings but not any commercial turnaround. The quarter saw expanded marketing efforts, with increased spending on digital initiatives, but with minimal GAAP revenue of $2,682 and declining cash (from $611,822 as of December 31, 2024 to $506,078 as of June 30, 2025), the financial picture remains strained.
Predictive Oncology operates at the intersection of artificial intelligence and oncology, using advanced software and a proprietary tumor biobank to assist biopharma partners in cancer drug discovery. The company leverages its AI platform, called PEDAL, and a collection of more than 150,000 patient tumor samples to build predictive models that identify and repurpose drug candidates for a variety of cancers.
Recently, the company has focused on transitioning from legacy offerings, such as 3D tumor models and kits, towards new pipelines centered on AI-powered drug discovery and commercializing proprietary assays. Key priorities include expanding the reach of ChemoFx, its primary live-cell drug response assay, and capitalizing on its biobank by building value-added partnerships.
Source Fool.com
